The prostatic sarcomas are exceedingly rare, constituting less than 0.1% of all primary prostate neoplasms. Although the importance of Ga-68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in prostate adenocarcinoma is well established, it is not useful in prostate sarcomas. Herein, we present fluorodeoxyglucose (18F-FDG) PET/CT findings of an 81-year-old man with a prostatic mass, which confirmed the diagnosis of leiomyosarcoma.
Öksüzoğlu et al. (Mon,) studied this question.